Skip to main content
Clinical Trials/NL-OMON54663
NL-OMON54663
Recruiting
Phase 2

A Proof of Concept, Phase IIa, Open Label Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients with Variegate Porphyria (VP)-related skin disease. - Phase IIa VP Study / CUV040

Clinuvel (UK) LTD0 sites3 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
Clinuvel (UK) LTD
Enrollment
3
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

Trial is onging in other countries

Registry
who.int
Start Date
TBD
End Date
December 28, 2023
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • Male or female patients with confirmed diagnosis of VP.
  • Patients with VP\-related skin symptoms assessed with a score equal or above 7
  • on the 11\-point VAS IGA.

Exclusion Criteria

  • Known allergy to afamelanotide or the polymer or to lignocaine/lidocaine or
  • other local anaesthetic.
  • Had two or more acute attacks of hepatic porphyria lasting more than two days,
  • within 12 months prior to the Screening period.
  • History of certain malignant and premalignant skin lesions.
  • Individual or family history of melanoma.
  • Severe hepatic disease.
  • Renal impairment (eGFR (MDRD) \< 30 ml/min\*1\.73m2\).
  • Female who is pregnant or lactating.
  • Females of child\-bearing potential not using adequate contraceptive measures.

Outcomes

Primary Outcomes

Not specified

Similar Trials